Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.012
Sell
RSI(14)
33.224
Neutral
STOCH(KDJ)(9,3,3)
42.100
Neutral
ATR(14)
0.249
High Vlolatility
CCI(14)
-240.446
Oversold
Williams %R
67.826
Sell
TRIX(12,20)
-0.477
Sell
StochRSI(14)
0.000
Sell
111 Inc
YI3.160USD
-0.533-14.44%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
160.13MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of 111 Inc
Currency: USD Updated: 2025-12-19Key Insights
111 Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 125/158 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
111 Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
111 Inc Highlights
StrengthsRisks
111 Inc is an investment holding company primarily engaged in the operation of integrated online and offline healthcare platform. The Company mainly operates its business through two segments. The Business to Customer (B2C) segment is engaged in the sale of pharmaceutical and other health and wellness products through 1 Medicine Marketplace, mobile apps, other online channels and offline pharmacies to consumers and certain enterprise customers. The Business to Business (B2B) segment is engaged in the sale of pharmaceutical products to pharmacies on 1 Pharmacy. The Company also provides customers with online consultation and electronic prescription services through the Internet hospital 1 Clinic. The Company’s products include drugs, nutritional supplements, medical supplies and devices and other products. The Company mainly conducts its business in the domestic market.
Fairly Valued
The company’s latest PE is -4.37, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.21M shares, decreasing 25.10% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 13.01K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of 111 Inc is 6.44, ranking 144/158 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 491.00M, representing a year-over-year decrease of 86.08%, while its net profit experienced a year-over-year decrease of 82.18%.
Score
Financials
5.38
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
2.52
Operational Efficiency
10.00
Growth Potential
7.08
Shareholder Returns
7.23
111 Inc's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of 111 Inc is 8.33, ranking 21/158 in the Pharmaceuticals industry. Its current P/E ratio is -4.37, which is -97.37% below the recent high of -0.11 and -132.31% above the recent low of -10.16.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 125/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19No earnings forecast score is currently available for 111 Inc. The Pharmaceuticals industry's average is 7.80.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
No Data
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of 111 Inc is 6.23, ranking 127/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 4.07 and the support level at 3.25, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.494
Sell
MA10
3.583
Sell
MA20
3.637
Sell
MA50
4.000
Sell
MA100
4.954
Sell
MA200
6.464
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of 111 Inc is 3.00, ranking 92/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 23.79%, representing a quarter-over-quarter decrease of 39.52%. The largest institutional shareholder is James Simons, holding a total of 13.01K shares, representing 0.26% of shares outstanding, with 1.54% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
First Pharmacia International
Susquehanna International Group, LLP
Morgan Stanley & Co. LLC
UBS Financial Services, Inc.
SBI Securities Co., Ltd.
J.P. Morgan Securities LLC
Parametric Portfolio Associates LLC
Rhumbline Advisers Ltd. Partnership
1
2
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of 111 Inc is 2.90, ranking 110/158 in the Pharmaceuticals industry. The company's beta value is 0.48. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.48
VaR
+7.51%
240-Day Maximum Drawdown
+69.64%
240-Day Volatility
+83.93%
Return
Best Daily Return
60 days
+6.93%
120 days
+6.93%
5 years
+49.54%
Worst Daily Return
60 days
-8.74%
120 days
-9.05%
5 years
-20.26%
Sharpe Ratio
60 days
-2.25
120 days
-2.64
5 years
-0.62
Risk Assessment
Maximum Drawdown
240 days
+69.64%
3 years
+89.99%
5 years
+98.25%
Return-to-Drawdown Ratio
240 days
-0.57
3 years
-0.32
5 years
-0.20
Skewness
240 days
+0.22
3 years
+2.07
5 years
+1.50
Volatility
Realised Volatility
240 days
+83.93%
5 years
+92.25%
Standardised True Range
240 days
+11.52%
5 years
+57.04%
Downside Risk-Adjusted Return
120 days
-355.69%
240 days
-355.69%
Maximum Daily Upside Volatility
60 days
+53.65%
Maximum Daily Downside Volatility
60 days
+53.00%
Liquidity
Average Turnover Rate
60 days
+0.07%
120 days
+0.09%
5 years
--
Turnover Deviation
20 days
-87.87%
60 days
-89.62%
120 days
-85.59%
Peer Comparison
Pharmaceuticals
111 Inc
YI
4.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
ANI Pharmaceuticals Inc
ANIP
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of 111 Inc?
The TradingKey Stock Score provides a comprehensive assessment of 111 Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of 111 Inc’s performance and outlook.
How do we generate the financial health score of 111 Inc?
To generate the financial health score of 111 Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects 111 Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of 111 Inc.
How do we generate the company valuation score of 111 Inc?
To generate the company valuation score of 111 Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare 111 Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of 111 Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of 111 Inc.
How do we generate the earnings forecast score of 111 Inc?
To calculate the earnings forecast score of 111 Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on 111 Inc’s future.
How do we generate the price momentum score of 111 Inc?
When generating the price momentum score for 111 Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of 111 Inc’s prices. A higher score indicates a more stable short-term price trend for 111 Inc.
How do we generate the institutional confidence score of 111 Inc?
To generate the institutional confidence score of 111 Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about 111 Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of 111 Inc.
How do we generate the risk management score of 111 Inc?
To assess the risk management score of 111 Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of 111 Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of 111 Inc.
